% alzhub.org library filter
% Source: https://alzhub.org/research?author=Lu+M&score_min=67
% 11 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{salloway2025-40390253,
  author  = {Salloway, S. and Pain, A. and Lee, E. and Papka, M. and Ferguson, M. B. and Wang, H. and Hu, H. and Lu, M. and others},
  title   = {{TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.70293},
  pmid    = {40390253},
  url     = {https://doi.org/10.1002/alz.70293}
}

@article{zimmer2025-40063015,
  author  = {Zimmer, J. A. and Ardayfio, P. and Wang, H. and Khanna, R. and Evans, C. D. and Lu, M. and Sparks, J. and Andersen, S. and Lauzon, S. and Nery, E. S. M. and others},
  title   = {{Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials}},
  journal = {JAMA Neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2025.0065},
  pmid    = {40063015},
  url     = {https://doi.org/10.1001/jamaneurol.2025.0065}
}

@article{pontecorvo2022-36251300,
  author  = {Pontecorvo, M. J. and Lu, M. and Burnham, S. C. and Schade, A. E. and Dage, J. L. and Shcherbinin, S. and Collins, E. C. and Sims, JR. and others},
  title   = {{Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.3392},
  pmid    = {36251300},
  url     = {https://doi.org/10.1001/jamaneurol.2022.3392}
}

@article{salloway2018-30129411,
  author  = {Salloway, S. and Marshall, G. A. and Lu, M. and Brashear, H. R.},
  title   = {{Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study}},
  journal = {Current Alzheimer research},
  year    = {2018},
  doi     = {10.2174/1567205015666180821114813},
  pmid    = {30129411},
  url     = {https://doi.org/10.2174/1567205015666180821114813}
}

@article{lu2025-41082199,
  author  = {Lu, M. and Kim, M. J. and Collins, E. C. and Shcherbinin, S. and Ellinwood, A. K. and Yokoi, Y. and Brooks, D. A. and Hansson, O. and others},
  title   = {{Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2025.3869},
  pmid    = {41082199},
  url     = {https://doi.org/10.1001/jamaneurol.2025.3869}
}

@article{shcherbinin2022-36094645,
  author  = {Shcherbinin, S. and Evans, C. D. and Lu, M. and Andersen, S. W. and Pontecorvo, M. J. and Willis, B. A. and Gueorguieva, I. and Hauck, P. M. and others},
  title   = {{Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.2793},
  pmid    = {36094645},
  url     = {https://doi.org/10.1001/jamaneurol.2022.2793}
}

@article{sims2023-9857475c,
  author  = {Sims, JR. and Zimmer, J. A. and Evans, C. D. and Lu, M. and Ardayfio, P. and Sparks, J. and Wessels, A. M. and Shcherbinin, S. and Wang, H. and Monkul Nery, E. S. and Collins, E. C. and Solomon, P. and Salloway, S. and Apostolova, L. G. and Hansson, O. and Ritchie, C. and Brooks, D. A. and Mintun, M. and Skovronsky, D. M. and {TRAILBLAZER-ALZ 2 Investigators}},
  title   = {{Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA},
  year    = {2023},
  pmid    = {37459141}
}

@article{sims2023-37459141,
  author  = {Sims, JR. and Zimmer, J. A. and Evans, C. D. and Lu, M. and Ardayfio, P. and Sparks, J. and Wessels, A. M. and Shcherbinin, S. and others},
  title   = {{Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA},
  year    = {2023},
  doi     = {10.1001/jama.2023.13239},
  pmid    = {37459141},
  url     = {https://doi.org/10.1001/jama.2023.13239}
}

@article{delnomdedieu2016-26925577,
  author  = {Delnomdedieu, M. and Duvvuri, S. and Li, D. J. and Atassi, N. and Lu, M. and Brashear, H. R. and Liu, E. and Ness, S. and others},
  title   = {{First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease}},
  journal = {Alzheimer's research \& therapy},
  year    = {2016},
  doi     = {10.1186/s13195-016-0177-y},
  pmid    = {26925577},
  url     = {https://doi.org/10.1186/s13195-016-0177-y}
}

@article{pontecorvo2019-31009046,
  author  = {Pontecorvo, M. J. and Devous, M. D. and Kennedy, I. and Navitsky, M. and Lu, M. and Galante, N. and Salloway, S. and Doraiswamy, P. M. and others},
  title   = {{A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia}},
  journal = {Brain : a journal of neurology},
  year    = {2019},
  doi     = {10.1093/brain/awz090},
  pmid    = {31009046},
  url     = {https://doi.org/10.1093/brain/awz090}
}

@article{fleisher2020-32338734,
  author  = {Fleisher, A. S. and Pontecorvo, M. J. and Devous, M. D. and Lu, M. and Arora, A. K. and Truocchio, S. P. and Aldea, P. and Flitter, M. and others},
  title   = {{Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes}},
  journal = {JAMA neurology},
  year    = {2020},
  doi     = {10.1001/jamaneurol.2020.0528},
  pmid    = {32338734},
  url     = {https://doi.org/10.1001/jamaneurol.2020.0528}
}